To assess the underlying effect of verlindamycin and ATRA treatment on neuroblastoma cells, we performed transcriptomics analysis of MYCN-amplified SK-N-BE(2)-C and non-MYCN-amplified SK-N-AS. The gene discussed is MYCN; the disease is neuroblastoma.